TP53 and mantle cell lymphoma: In newly diagnosed MCL patients with bone marrow involvement of ≥5%, concurrent TP53 aberrations (i.e., mutation or deletion) and CDKN2A deletions conferred a shortened event-free survival of 3 months and an overall survival of 10 months following treatment with frontline immunochemotherapy [46].